Demand for HPAPIs drives Patheon to invest $1m in UK facility

By Dan Stanton

- Last updated on GMT

Related tags Investment

Patheon upgrades UK facility due to HPAPI demand
Patheon upgrades UK facility due to HPAPI demand
Increasing demand for HPAPIs has driven Patheon to invest in its Milton Park, UK manufacturing facility, the company says.

Patheon is investing £600,000 ($1m) into the UK facility, upgrading it to add instrumented compression, automated encapsulation and coating capabilities in order to offer its clients a “choice of capabilities not previously available that are linked to a network of larger scale sites that are also located in EU,”​ according to Milton Park General manager Mike Mencer.

Whilst Mencer could not divulge information of specific customers or development projects to us, he did tell this publication the investment is being driven by an increasing demand for Early Development needs for highly potent active pharmaceutical ingredients HPAPIs (as well as lower potency ones).

“Within the industry, the HPAPIs market is estimated to grow by 8.4% from 2009 to 2015 versus 6.3% in previous years,”​ he said, “and is comprised of both small molecule and biologics.”

He continued: “Because Patheon is seen as the leader in contracted pharmaceutical development services [see here​], it made sense to invest in additional capabilities to support the market demands.

“We see an increase in the demand for highly potent products, both those in development and those that are approved and being commercially produced, across all sectors of the Pharma industry.”

The expansion - expected to lead to the creation of at least 8-10 new highly skilled and technical jobs, according to Mencer – comes almost exactly a year since Patheon last invested in the site.

That investment was for new drug delivery technologies including hot melt extrusion and spray-drying at the Oxfordshire site and was announced last February​ for an undisclosed but “modest”​ upgrade cost.

European HPAPIs

Patheon joins a growing list of manufacturers investing in HPAPI capabilities in Europe, with other examples including Evonik​, Novasep​ and Aesica.

“HPAPIs form 10% of the overall market and are continuing to grow with a large number of discoveries for these compounds being made in Europe,”​ said Marvin Faber, senior director, corporate EH&S, Patheon. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more